What’s going on with the AstraZeneca share price?

The AstraZeneca share price has been treading water for some time. Dr James Fox takes a closer look at possible catalysts, including a rising dividend.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Concept of two young professional men looking at a screen in a technological data centre

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE:AZN) share price has fallen 8.4% over the past 12 months. It’s underperformed the wider FTSE 100. That’s certainly not something I thought I’d say a year ago. So, what’s going on with it?

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Moving sideways

It’s been an underwhelming year for AstraZeneca stock, and there are no obvious reasons for this. The oncology-focused company is up 75.6% over five years, and it appears to have reached something of a plateau.

One setback was the perceived disappointing results of its datopotamab deruxtecan lung cancer trial in October. Jefferies analyst Stephen Barker suggested the trial results were “worse-than-expected,’ noting only a marginal improve in the condition of non-small cell lung cancer.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

However, the US Food and Drug Administration has since been given the green light for the treatment for patients with treated advanced nonsquamous non-small cell lung cancer.

Datopotamab deruxtecan is just one of several factors that could have negatively impacted the share price. Of course, with AstraZeneca receiving a lot of attention during the pandemic, investors may have simply found better value elsewhere. The below chart tracks the company’s momentum over the past 12 months.

Source: TradingView

Possible catalysts

One possible catalyst for share price growth was announced on Thursday 11 April. Ahead of a key shareholder vote on pay for its long-standing chief executive Pascal Soriot, AstraZeneca promised to increase its dividend by 7% this year. The dividend yield currently sits at 2.12% — not particularly exciting.

The stock was up 1.1% in early trading.

There are also several catalysts in the form of drug approvals, including breast cancer treatment Truqap and nerve disorder treatment Wainua in the US. Imfinzi, which contributes an impressive 9% of the company’s revenues, was approved in China in November. Depending on the uptake in this huge market, it could be a substantial boost.

There’s also the matter of improved guidance. Management recently revised guidance upwards from the “high single-digit to low double-digit percentage.” If it can come through and start showing evidence of this, I’d expect further upward movement in the share price.

Of course, there are always ups and downs in drug and treatment development. Some treatments fail despite millions of pounds of investment.

Valuations

AstraZeneca certainly doesn’t look like bad value. The pharma giant is currently trading at 16.8 times forward earnings, representing a 14.2% discount to the wider healthcare industry. And given modest growth expectations, this forward price-to-earnings (P/E) ratio falls to 14.5 times in 2025 and 12.5 times in 2026.

For me, one of the most important metrics is the price-to-earnings-to-growth (PEG) ratio. This is essentially the forward P/E ratio divided by the expected average annualised growth rate over the medium term. AstraZeneca’s PEG ratio is 1.4. Coupled with the small but handy dividend yield, this doesn’t scream value.

However, with global populations ageing and treatment costs becoming more realistic in the developing world, a lot of the value for pharma stocks is beyond the medium term.

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

At a 52-week low but forecast to rise 73%! Is this growth share the FTSE’s top recovery play? 

This FTSE 100 growth share has taken an absolute beating over the past two years but Harvey Jones says the…

Read more »

Investing Articles

This FTSE 250 share offers a juicy 9.8% yield. Will it last?

This well-known FTSE 250 share has a percentage dividend yield approaching double digits. Should Christopher Ruane add the income share…

Read more »

Investing Articles

Is a £333,000 portfolio enough to retire and live off passive income?

A third of a million pounds can generate a serious amount of passive income, but relying on this sum alone…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing For Beginners

Why FTSE 100 investors should pay attention to ‘Liberation Day’

Jon Smith explains why the upcoming tariff announcement from across the pond could have an impact on the FTSE 100,…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Here’s why Nvidia stock fell 13% in March

The Nvidia stock price rise was looking unstoppable. Should investors now be wondering if the same might be true of…

Read more »

US Stock

It’s ISA deadline week! Here’s my 3-step game plan

Jon Smith tries to calm the hype around the last minute ISA rush to buy stocks and explains why he's…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£10,000 invested in BAE Systems shares at Christmas is now worth…

BAE Systems shares have been surging in the FTSE 100 in 2025, driven higher by the wavering US commitment to…

Read more »

Investing Articles

Up 19% in 2 weeks, can the Tesla share price rebound further?

Tesla's first-quarter delivery numbers came out today. Will they help persuade our writer to invest his money at the current…

Read more »